GPCR vs. BBIO, OGN, IONS, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
Structure Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Structure Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma presently has a consensus target price of $47.62, indicating a potential upside of 69.99%. Structure Therapeutics has a consensus target price of $83.13, indicating a potential upside of 143.06%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than BridgeBio Pharma.
In the previous week, BridgeBio Pharma had 10 more articles in the media than Structure Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 8 mentions for Structure Therapeutics. BridgeBio Pharma's average media sentiment score of 0.91 beat Structure Therapeutics' score of 0.47 indicating that Structure Therapeutics is being referred to more favorably in the news media.
BridgeBio Pharma received 128 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Structure Therapeutics an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
Structure Therapeutics has a net margin of 0.00% compared to Structure Therapeutics' net margin of -246.24%. Structure Therapeutics' return on equity of 0.00% beat BridgeBio Pharma's return on equity.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
BridgeBio Pharma beats Structure Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
